Adial Pharmaceuticals Inc (ADIL) Stock Price, Quote & News

Company Profile

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and i...

Industry: Biotechnology

Sector: Healthcare

Phone: 804 487 8196

Website: www.adial.com

Address:

4870 Sadler Road, Suite 300, Glen Allen, United States

InputInv Dec. 25 at 9:51 AM

$ADIL Capital discipline has become the critical gating factor, as investors weigh durability over pace. Clear follow‑through could unlock sustainable re‑rating.

0 · Reply

DarkSonar Dec. 23 at 4:16 PM

$ADIL Whole Market is red and this stock staying BULLISH with a massive $0.007 move!!! Seven tenths of a penny!!! 😅

1 · Reply

Mahdinur Dec. 23 at 3:44 PM

$ADIL lol you killing the comment section. Fda good comments

1 · Reply

kedute Dec. 23 at 11:47 AM

$ADIL added one more small chunk again - equal my my monthly alcohol consumption expenditure.

0 · Reply

TWITLIEDETECTOR Dec. 23 at 5:00 AM

$ADIL this either goes over a buck very soon or an RS

0 · Reply

dogood Dec. 22 at 9:14 PM

$ADIL this should have been $10 with good news but we are stuck below .30

0 · Reply

Perfect_Thinking Dec. 22 at 4:04 PM

$ADIL looking like some news might drop this week..

2 · Reply

TWITLIEDETECTOR Dec. 20 at 3:34 AM

$ADIL safe from an RS announcement a bit longer. tempting to buy now low enough to protect from a pr of an rs

0 · Reply

dln101 Dec. 19 at 7:40 PM

$ADIL next $LAZR ? 🤔

0 · Reply

Perfect_Thinking Dec. 19 at 6:18 PM

$ADIL This can't be so low by eoy, it needs atleast .35 to holdon some manipulation is happening. Hope that they drop some PR soon before it dilutes..

0 · Reply

Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show

Oct 9, 2025, 8:30 AM EDT - 2 months ago

Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution

Sep 16, 2025, 8:00 AM EDT - 3 months ago

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Sep 3, 2025, 8:30 AM EDT - 4 months ago

Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule

Aug 14, 2025, 8:30 AM EDT - 4 months ago

Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 8:00 AM EDT - 5 months ago

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

Jul 16, 2025, 8:30 AM EDT - 5 months ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

Jul 9, 2025, 8:30 AM EDT - 6 months ago

Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045

Jun 25, 2025, 8:30 AM EDT - 6 months ago

Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

May 15, 2025, 8:30 AM EDT - 8 months ago

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 8:30 AM EDT - 8 months ago

Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

May 2, 2025, 11:48 AM EDT - 8 months ago

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds

May 1, 2025, 8:30 AM EDT - 8 months ago

Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders

Mar 4, 2025, 8:30 AM EST - 10 months ago

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

Feb 25, 2025, 9:00 AM EST - 10 months ago

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Feb 19, 2025, 9:00 AM EST - 11 months ago

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Feb 12, 2025, 9:00 AM EST - 11 months ago

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Jan 29, 2025, 9:00 AM EST - 11 months ago

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Dec 3, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Nov 5, 2024, 8:30 AM EST - 1 year ago

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Sep 19, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Jul 23, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

May 29, 2024, 8:30 AM EDT - 1 year ago

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

May 15, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Apr 10, 2024, 2:15 PM EDT - 1 year ago

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Apr 10, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Apr 2, 2024, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Mar 1, 2024, 7:00 PM EST - 1 year ago

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Feb 28, 2024, 9:30 AM EST - 1 year ago

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Feb 15, 2024, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Feb 13, 2024, 9:15 AM EST - 2 years ago

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Jan 18, 2024, 8:30 AM EST - 2 years ago

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Dec 20, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Nov 29, 2023, 4:05 PM EST - 2 years ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Nov 14, 2023, 5:02 PM EST - 2 years ago

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 31, 2023, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Oct 24, 2023, 4:30 PM EDT - 2 years ago

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 20, 2023, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 19, 2023, 12:00 PM EDT - 2 years ago

Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

Oct 19, 2023, 10:30 AM EDT - 2 years ago

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Oct 18, 2023, 8:00 AM EDT - 2 years ago

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

Sep 28, 2023, 7:00 AM EDT - 2 years ago

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

InputInv Dec. 25 at 9:51 AM

$ADIL Capital discipline has become the critical gating factor, as investors weigh durability over pace. Clear follow‑through could unlock sustainable re‑rating.

0 · Reply

DarkSonar Dec. 23 at 4:16 PM

$ADIL Whole Market is red and this stock staying BULLISH with a massive $0.007 move!!! Seven tenths of a penny!!! 😅

1 · Reply

Mahdinur Dec. 23 at 3:44 PM

$ADIL lol you killing the comment section. Fda good comments

1 · Reply

kedute Dec. 23 at 11:47 AM

$ADIL added one more small chunk again - equal my my monthly alcohol consumption expenditure.

0 · Reply

TWITLIEDETECTOR Dec. 23 at 5:00 AM

$ADIL this either goes over a buck very soon or an RS

0 · Reply

dogood Dec. 22 at 9:14 PM

$ADIL this should have been $10 with good news but we are stuck below .30

0 · Reply

Perfect_Thinking Dec. 22 at 4:04 PM

$ADIL looking like some news might drop this week..

2 · Reply

TWITLIEDETECTOR Dec. 20 at 3:34 AM

$ADIL safe from an RS announcement a bit longer. tempting to buy now low enough to protect from a pr of an rs

0 · Reply

dln101 Dec. 19 at 7:40 PM

$ADIL next $LAZR ? 🤔

0 · Reply

Perfect_Thinking Dec. 19 at 6:18 PM

$ADIL This can't be so low by eoy, it needs atleast .35 to holdon some manipulation is happening. Hope that they drop some PR soon before it dilutes..

0 · Reply

Mahdinur Dec. 19 at 2:20 AM

$GRI Look at that bid! $ADIL $NOW $DFLI $PAVS will never see such an imbalance

0 · Reply

DarkSonar Dec. 18 at 7:51 PM

$ADIL Average weekly volume (last 2 months) is decimated but I am guessing not totally bad for a 24M share float. Interesting situation but highly risky. I made some money last time due to chart getting propped up so I stepped out of this position. 🔬

0 · Reply

DarkSonar Dec. 18 at 7:32 PM

$ADIL Some of these metrics are always a good sign but they don’t even believe in their own company . Still, this stock likes to run when they need money 😅

0 · Reply

DarkSonar Dec. 18 at 6:04 PM

$ADIL Looking good for reentry, nearing compliance in March and a possible Double Bottom if they don’t release some sucker punching news about Splits then don’t see why this shouldn’t have a little move upwards. Monitoring. LETS GO!!! 📈📈📈📈📈📈📈

0 · Reply